281 related articles for article (PubMed ID: 31623302)
1. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
3. Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma.
Soerensen AV; Ellebaek E; Bastholt L; Schmidt H; Donia M; Svane IM
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32932758
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients.
Grynberg S; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Haisraely O; Lawrence Y; Ben-Betzalel G
Ther Adv Med Oncol; 2022; 14():17588359221131521. PubMed ID: 36339927
[TBL] [Abstract][Full Text] [Related]
5. Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study.
Vanaken L; Woei-A-Jin FJSH; Van Ginderdeuren R; Deroose CM; Laenen A; Missotten G; Thal DR; Bechter O; Schöffski P; Clement P
Acta Oncol; 2023 May; 62(5):480-487. PubMed ID: 37200223
[TBL] [Abstract][Full Text] [Related]
6. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
7. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
8. The real-world impact of modern treatments on the survival of patients with metastatic melanoma.
Donia M; Ellebaek E; Øllegaard TH; Duval L; Aaby JB; Hoejberg L; Køhler UH; Schmidt H; Bastholt L; Svane IM
Eur J Cancer; 2019 Feb; 108():25-32. PubMed ID: 30605822
[TBL] [Abstract][Full Text] [Related]
9. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
10. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
12. Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: A retrospective study from the United States database.
Adhikari A; Cha E; Antala D; Sapkota S; Bhattarai U
Cancer Epidemiol; 2022 Dec; 81():102254. PubMed ID: 36162155
[TBL] [Abstract][Full Text] [Related]
13. Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Blomen CL; Kött J; Hartung TI; Torster LK; Gebhardt C
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945010
[TBL] [Abstract][Full Text] [Related]
14. Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D; Rose AAN; Muniz TP; Hogg D; Butler MO; Saibil SD; King I; Kamil ZS; Ghazarian D; Ross K; Iafolla M; Araujo DV; Waldron J; Laperriere N; Krema H; Spreafico A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298857
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study.
Haist M; Stege H; Pemler S; Heinz J; Fleischer MI; Graf C; Ruf W; Loquai C; Grabbe S
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680252
[TBL] [Abstract][Full Text] [Related]
16. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
17. NCDB Analysis of Melanoma 2004-2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval.
Singh SRK; Malapati SJ; Kumar R; Willner C; Wang D
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33810182
[No Abstract] [Full Text] [Related]
18. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.
Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C
Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
